Short BIOGRAPHICAL SKETCH ( updated January 2020)) EZIO GIACOBINI, MD, PhD.Professor Emeritus M. D. 1953 (Turin, Italy); certified M. D. 1960 (Italy); certified M. D. 2003 (Switzerland); PhD. 1959 (Cellular Neuropharmacology (Karolinska Institute, Stockholm, Sweden); Honorary M.D. 2000 (University of Kuopio, Finland); Staff physician and clinical investigator in Psychiatry (1953-1971).Since July 1995 is a professor associated with the Dept. of Internal Medicine, Rehabilitation and Geriatrics, University of Geneva Medical School in Geneva, Switzerland and an Adjunct Professor of Pharmacology, Psychiatry and Neurology at the Southern Illinois School of Medicine, Springfield, IL, USA. From Janury 1982 until June 1995 he was a Professor and Chairman of the Dept. of Pharmacology and Scientific Director of the NIA (NIH) Alzheimer Center at Southern Illinois University School of Medicine, Springfield IL, USA. Before January 1982, he was Professor of Biobehavioral Science at the University of Connecticut, Storrs, CT and head of the laboratory of neuro-psychopharmacology.His major research interest is in the pre-clinical and clinical development of drug therapy for Alzheimer’s disease. Together with R. Becker he has developed, preclinically and clinically, two new cholinesterase inhibitors (metrifonate and pentastigmine ) and participated in the clinical development of E20-20 ( donepezil) , rivastigmine and phenserine. He also did research is in the area of a-beta oligomers , their origin, localization and relation to Alzheimer pathology .New drug development for AD continues to be his main task of research. He received the LIFE TIME ACHIEVEMENT AWARD IN ALZHEIMER’S DISEASE RESEARCH from the Alzheimer Association (USA) at the 8th Int. Conference on Alzheimer’s Disease in Stockholm, July 2002. Organizer of the Springfield Symposium on Advances in Alzheimer therapy ( 1988-2018). Co-organizer of AAT-AD-PD meeting since 2020. Next meeting will be in GOTHENBURG, mars 2023.